Hou Lin, Li Xiaodong, Su Chang, Chen Kailin, Qu Maoxing
Institute of Cancer Stem Cell, Dalian Medical University, Dalian, China.
First Clinical College, The First Afiliated Hospital of Dalian Medical University, Dalian, China.
Front Oncol. 2022 Aug 25;12:920707. doi: 10.3389/fonc.2022.920707. eCollection 2022.
The pathogenesis of ischemia-reperfusion injury is not fully understood, most of the current clinical treatment methods mainly relieve symptoms, and cannot prevent fundamentally. The mechanism of Ferroptosis has been extensively studied in recent years, but primarily focused on its therapeutic effects on tumors. After careful comparison, it is easy to find that the symptoms of ischemia-reperfusion injury often accompany by increased lipid peroxidation and increased intracellular iron level are the same as the manifestations of iron-dependent non-apoptotic Ferroptosis. Based on this "coincidence", we launched this survey. After reading a lot of literature, we found that Ferroptosis is the first step of ischemia-reperfusion injury, and cell necrosis and inflammation are the subsequent steps secondary to Ferroptosis. In this review, we have collected and sorted out the current knowledge about the role and targets of Ferroptosis in the process of ischemia-reperfusion injury. And future studies may be biased towards exploring the use of ferroptosis inhibitors in combination with other treatment options.
缺血再灌注损伤的发病机制尚未完全明确，目前大多数临床治疗方法主要是缓解症状，无法从根本上预防。近年来，铁死亡的机制得到了广泛研究，但主要集中在其对肿瘤的治疗作用上。经过仔细比较，很容易发现缺血再灌注损伤的症状往往伴随着脂质过氧化增加和细胞内铁水平升高，这与铁依赖性非凋亡性铁死亡的表现相同。基于这一“巧合”，我们开展了这项研究。在阅读了大量文献后，我们发现铁死亡是缺血再灌注损伤的第一步，细胞坏死和炎症是继铁死亡之后的后续步骤。在这篇综述中，我们收集并整理了目前关于铁死亡在缺血再灌注损伤过程中的作用和靶点的知识。未来的研究可能倾向于探索铁死亡抑制剂与其他治疗方案联合使用。
